EGFR-IN-134
EGFR-IN-134 (compound 3f), a triazolo[3,4-a]isoquinoline derivative, is a potent EGFR inhibitor with an IC50 of 0.023 µM. EGFR-IN-134 induces apoptosis and necrosis. EGFR-IN-134 initiates cell cycle arrest at the G2/M and pre-G1 phases, downregulates anti-apoptotic protein Bcl2 and upregulates pro-apoptotic proteins: p53, Bax, and caspases 3, 8, and 9. EGFR-IN-134 shows antiproliferative and anticancer activity[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family; Caspase; EGFR; MDM-2/p53; Necroptosis
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-in-134.html
Smiles
O=C(C1=NN(C2=CC=C([N+]([O-])=O)C=C2)C3N1CCC4=C3C=C(OC)C(OC)=C4)/C=C/C5=CN(C6=CC=CC=C6)N=C5C7=CC=CC=C7
Molecular Formula
C36H30N6O5
Molecular Weight
626.66
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bax; Bcl-2; Caspase 3; Caspase 8; Caspase 9; EGFR/ErbB1/HER1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD63 (MX-49.129.5), CF640R conjugate, 0.1mg/mL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF740 conjugate, 0.1mg/mL
Histone H1 (AE-4), CF594 conjugate, 0.1mg/mL
TGF-beta (1D11.16.8), CF770 conjugate, 0.1mg/mL
